<DOC>
	<DOC>NCT00514514</DOC>
	<brief_summary>The purpose of this study is to compare renal function of immunosuppressive regimens with different relevance of the calcineurin inhibitor (CNI) cyclosporine: standard dose CNI, low dose CNI, CNI free in de novo kidney transplant patients after 12 months of therapy.</brief_summary>
	<brief_title>Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Inclusion criteria Males or females, aged 18 70 years Recipients of de novo cadaveric, living unrelated or living related kidney transplants Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at screening, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility. Patients who are willing and able to participate in the study and from whom written informed consent has been obtained. Exclusion criteria More than one previous renal transplantation Multiorgan recipients (e.g., kidney and pancreas) or previous transplant with any other organ, different from kidney Patients receiving a kidney from a nonheart beating donor Donor age: &lt; 5 years or &gt; 70 years Graft loss due to immunological reasons in the first year after transplantation (in case of secondary transplantation) Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Everolimus</keyword>
	<keyword>mycophenolate</keyword>
	<keyword>CNI-free</keyword>
	<keyword>kidney transplantation</keyword>
</DOC>